Neurolixis Inc. has in-licensed early-stage clinical assets (Phase 1 and Phase 2) for repurposing in indications with unmet needs in psychiatric and neurological disorders. More...

Research Grants

Neurolixis has been awarded several research grants by private foundations, including the International Rett Syndrome Foundation and the Michael J. Fox Foundation for Parkinson's research. More...


Neurolixis is developing clinical phase drugs targeting L-DOPA-induced dyskinesia in Parkinson's disease and breathing deficits in Rett syndrome, an orphan disorder. See the latest News

Neurolixis - contact@neurolixis.com

copyright  ¬©Neurolixis - 2011